ROCHE HLDGS AG (RHHBY)

30.59
OTC Markets
Prev Close 29.84
Day Low/High 30.55 / 30.85
52 Wk Low/High 26.30 / 32.42
Exchange OTC Markets
Shares Outstanding 702.56B
Market Cap 167.69B
Div & Yield N.A. (N.A)

Latest News

SQZ Biotech Expands Cell Therapy Partnership With Roche To Develop Antigen Presenting Cells For Immune-Oncology

SQZ Biotech Expands Cell Therapy Partnership With Roche To Develop Antigen Presenting Cells For Immune-Oncology

- Collaboration combines SQZ Biotech's novel cell therapy platform with Roche's cancer immunotherapy expertise

Genentech's Kadcyla Reduced The Risk Of Disease Recurring In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech's Kadcyla Reduced The Risk Of Disease Recurring In People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (ado-trastuzumab emtansine) as a single agent significantly reduced the risk of disease...

OCREVUS (Ocrelizumab) Data Show Early Initiation Of Treatment Reduces Disability Progression Over Five Years In Relapsing And Primary Progressive Multiple Sclerosis

OCREVUS (Ocrelizumab) Data Show Early Initiation Of Treatment Reduces Disability Progression Over Five Years In Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from...

Genentech To Present New Positive Data From Its Broad Cancer Immunotherapy Program And Across A Wide Range Of Cancers At The European Society For Medical Oncology (ESMO) 2018 Congress

Genentech To Present New Positive Data From Its Broad Cancer Immunotherapy Program And Across A Wide Range Of Cancers At The European Society For Medical Oncology (ESMO) 2018 Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new results from a number of studies across its industry-leading oncology portfolio of approved and investigational medicines will be presented at the European...

FDA Approves Genentech's Hemlibra (Emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors

FDA Approves Genentech's Hemlibra (Emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Positive Phase III Results For Baloxavir Marboxil In People At High Risk Of Complications From Influenza To Be Presented At IDWeek 2018

Positive Phase III Results For Baloxavir Marboxil In People At High Risk Of Complications From Influenza To Be Presented At IDWeek 2018

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo (median...

Genentech Announces New Data For Risdiplam In Spinal Muscular Atrophy (SMA) At The World Muscle Society Congress

Genentech Announces New Data For Risdiplam In Spinal Muscular Atrophy (SMA) At The World Muscle Society Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam (RG7916) in spinal muscular atrophy (SMA).

Genentech To Present Five-Year OCREVUS (Ocrelizumab) Efficacy And Safety Data In Relapsing And Primary Progressive Multiple Sclerosis At ECTRIMS

Genentech To Present Five-Year OCREVUS (Ocrelizumab) Efficacy And Safety Data In Relapsing And Primary Progressive Multiple Sclerosis At ECTRIMS

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of MS will be presented during the 34th Congress of the European Committee...

FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation

FDA Approves Genentech's Xolair (Omalizumab) Prefilled Syringe Formulation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People Live Significantly Longer As An Initial Treatment For People With Extensive-Stage Small Cell Lung Cancer

Genentech's TECENTRIQ In Combination With Chemotherapy Helped People Live Significantly Longer As An Initial Treatment For People With Extensive-Stage Small Cell Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpower133 study of TECENTRIQ ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of...

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In A Type Of Previously Untreated Advanced Lung Cancer

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In A Type Of Previously Untreated Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III IMpower132 study of TECENTRIQ ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial...

Genentech's Investigational Medicine Entrectinib Showed A Durable Response Of More Than Two Years In People With A Specific Type Of Lung Cancer

Genentech's Investigational Medicine Entrectinib Showed A Durable Response Of More Than Two Years In People With A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA trials, which...

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Systemic Juvenile Idiopathic Arthritis (SJIA), A Rare Form Of Juvenile Arthritis

FDA Approves Subcutaneous Formulation Of Actemra For Use In Active Systemic Juvenile Idiopathic Arthritis (SJIA), A Rare Form Of Juvenile Arthritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech To Present New Data From Its Extensive Lung Cancer Program At The 2018 World Conference On Lung Cancer (WCLC)

Genentech To Present New Data From Its Extensive Lung Cancer Program At The 2018 World Conference On Lung Cancer (WCLC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from its broad clinical development program across different types of lung cancer will be presented at the International Association for the Study of Lung...

3 Biotech Stocks Ready to Burn Up

3 Biotech Stocks Ready to Burn Up

Biotechs are known for wild tears. Investors, you'll want to consider these drug makers.

Positive Phase III Results For Genentech's HEMLIBRA (emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors Published In New England Journal Of Medicine

Positive Phase III Results For Genentech's HEMLIBRA (emicizumab-kxwh) For Hemophilia A Without Factor VIII Inhibitors Published In New England Journal Of Medicine

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that pivotal data from the Phase III HAVEN 3 study, which evaluated HEMLIBRA ® (emicizumab-kxwh) prophylaxis administered every week or every two weeks in adults and...

Roche Receives FDA Approval For Cobas EGFR Mutation Test V2 As Companion Diagnostic With IRESSA (gefitinib) In First-line Treatment Of Patients With Non-small Cell Lung Cancer (NSCLC)

Roche Receives FDA Approval For Cobas EGFR Mutation Test V2 As Companion Diagnostic With IRESSA (gefitinib) In First-line Treatment Of Patients With Non-small Cell Lung Cancer (NSCLC)

- New indication approval for cobas EGFR Mutation Test v2 as companion diagnostic, follows previous approvals with Tarceva (erlotinib) and TAGRISSO (osimertinib)

New Cervical Cancer Screening Guidelines Recommend HPV Testing Alone

New Cervical Cancer Screening Guidelines Recommend HPV Testing Alone

- US Preventive Services Task Force updated guidelines add primary HPV testing as recommended screening method for women 30-65

FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies

FDA Grants Breakthrough Therapy Designation For Xolair (Omalizumab) For Food Allergies

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Roche To Showcase How Labs Are Driving Change Across Health Networks To Address PAMA And Other Challenges At AACC 2018 Clinical Lab Expo

Roche To Showcase How Labs Are Driving Change Across Health Networks To Address PAMA And Other Challenges At AACC 2018 Clinical Lab Expo

- Featured labs address challenges by streamlining processes, reducing costs and optimizing operations while ensuring delivery of care

Roche's Cobas HPV Test Receives FDA Approval For First-line Cervical Cancer Screening Using SurePath Preservative Fluid

Roche's Cobas HPV Test Receives FDA Approval For First-line Cervical Cancer Screening Using SurePath Preservative Fluid

- Roche test is now the only HPV test approved for first-line screening with two most common collection media for Pap tests

Genentech's Port Delivery System With Ranibizumab (PDS) Implant In Eye With Refill Needle (Graphic: Business Wire)

Genentech's Port Delivery System With Ranibizumab (PDS) Implant In Eye With Refill Needle (Graphic: Business Wire)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study evaluating the efficacy and safety of its investigational Port Delivery System with ranibizumab (PDS) in people...

Genentech To Present New Data Demonstrating The Breadth And Depth Of Its Alzheimer's Program At The Upcoming Alzheimer's Association International Conference (AAIC)

Genentech To Present New Data Demonstrating The Breadth And Depth Of Its Alzheimer's Program At The Upcoming Alzheimer's Association International Conference (AAIC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will present 16 new data presentations across its Alzheimer's disease (AD) pipeline at this year's Alzheimer's Association International Conference (AAIC) from...

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With Advanced Lung Cancer

Genentech's TECENTRIQ In Combination With Pemetrexed And Platinum-Based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With Advanced Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of TECENTRIQ ® (atezolizumab)...

FDA Grants Breakthrough Therapy Designation For Genentech's TECENTRIQ In Combination With Avastin As First-Line Treatment For Advanced Or Metastatic Hepatocellular Carcinoma (HCC)

FDA Grants Breakthrough Therapy Designation For Genentech's TECENTRIQ In Combination With Avastin As First-Line Treatment For Advanced Or Metastatic Hepatocellular Carcinoma (HCC)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms In People At High Risk Of Complications From The Flu

Phase III CAPSTONE-2 Study Showed That Baloxavir Marboxil Reduced Symptoms In People At High Risk Of Complications From The Flu

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study's primary...

Roche PCT Assay Cleared For Expanded Use - Important Tool In Antibiotic Resistance Crisis

Roche PCT Assay Cleared For Expanded Use - Important Tool In Antibiotic Resistance Crisis

Elecsys® B·R·A·H·M·S PCT™ (procalcitonin) helps clinicians assess presence and severity of certain bacterial infections and patient response to antibiotics

Genentech Announces Submission Of Supplemental New Drug Application For Venclexta For People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy

Genentech Announces Submission Of Supplemental New Drug Application For Venclexta For People With Previously Untreated Acute Myeloid Leukemia Who Are Ineligible For Intensive Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced submission of a supplemental New Drug Application (sNDA) to the U.